Sequential administration of PD‑1 inhibitor and cetuximab causes pneumonia

Severe drug-induced lung injury (DLI) has been reported to be associated with sequential administration of osimertinib, a third-generation tyrosine kinase inhibitor, following a programmed cell death ligand 1 (PD-L1) inhibitor. However, the relationship of sequential treatment with an anti-epidermal...

Descripción completa

Detalles Bibliográficos
Autores principales: Arai, Makoto, Abe, Mitsuhiro, Kitahara, Shinsuke, Sakuma, Noriko, Ohno, Izumi, Takahashi, Koji, Imai, Chiaki, Saeki, Hiromi, Suzuki, Takuji, Uzawa, Katsuhiro, Hanazawa, Toyoyuki, Takiguchi, Yuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236250/
https://www.ncbi.nlm.nih.gov/pubmed/37274471
http://dx.doi.org/10.3892/ol.2023.13874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236250/
https://www.ncbi.nlm.nih.gov/pubmed/37274471
http://dx.doi.org/10.3892/ol.2023.13874

Ejemplares similares